ライフサイエンスコーパス: seasonal influenza

1 r significantly when comparing pandemic with seasonal influenza.

2 ck/sepsis, and organ failure than those with seasonal influenza.

3 H1N1pdm09 than persons of the same ages with seasonal influenza.

4 ansmission patterns previously described for seasonal influenza.

5 ss hospitalizations that are attributable to seasonal influenza.

6 increase was not greater than observed with seasonal influenza.

7 spitalization, and high mortality similar to seasonal influenza.

8 ly rigorous system for real-time forecast of seasonal influenza.

9 that likely exceeds excess mortality due to seasonal influenza.

10 tory disease in HCT recipients compared with seasonal influenza.

11 ve activity, and compared characteristics to seasonal influenza.

12 s sensitive for 2009 H1N1 influenza than for seasonal influenza.

13 viduals presented with symptoms atypical for seasonal influenza.

14 ILI) reports to create a weekly forecast for seasonal influenza.

15 ncidence and rates of antigenic evolution of seasonal influenza?

16 serial passage in MDCK cells inoculated with seasonal influenza A (H1N1) viruses at a low multiplicit

17 Seasonal influenza A and B outcomes were similar.

18 The strategy was validated on thousands of seasonal influenza A and B virus-positive specimens usin

19 [HA], neuraminidase [NA], and matrix [M]) of seasonal influenza A and B viruses for next-generation s

20 Recent serological studies of seasonal influenza A in humans suggest a striking charac

21 dy responses, individuals vaccinated against seasonal influenza A may still benefit from preexisting

22 o the high morbidity and mortality caused by seasonal influenza A virus (IAV) infections in older ind

23 be school-aged, compared with patients with seasonal influenza A virus infection (prevalence ratio [

24 nd influenza-associated pneumonia similar to seasonal influenza A virus infection and accounts for a

25 ded more school-aged children, compared with seasonal influenza A virus infection and noninfluenza IL

26 )pdm09 infection were compared to those with seasonal influenza A virus infection and those with ILI

27 Mixed infections with seasonal influenza A virus strains are a common occurren

28 vity between these viruses and current human seasonal influenza A virus strains.

29 valent influenza vaccine (sTIV) containing a seasonal influenza A virus subtype H1N1 (A[H1N1]) compon

30 occurred as a second epidemic peak following seasonal influenza A virus subtype H3N2 cases in 2009 an

31 Seasonal influenza A virus subtypes H1N1 and H3N2 and in

32 The seasonal influenza A virus undergoes rapid evolution to

33 Seasonal influenza A viruses (IAV) originate from pandem

34 ting influenza virus pathogenesis.IMPORTANCE Seasonal influenza A viruses (IAVs) are among the most c

35 proteases are critical for activating HAs of seasonal influenza A viruses (IAVs) in humans.

36 Seasonal influenza A viruses cause annual epidemics of r

37 iod, with 20 discrete introductions of human seasonal influenza A viruses showing sustained onward tr

38 regulates IFN production during infection by seasonal influenza A viruses that activate IRF3 and IFN

39 STAT1 activation during infection with other seasonal influenza A viruses that activate IRF3.

40 We tested specimens for seasonal influenza A viruses, using real-time reverse-tr

41 pdm09 were cross-reactive with M2 protein of seasonal influenza A viruses.

42 human population, specifically two types of seasonal influenza A viruses: (i) H3N2 and H1N1 viruses

43 2) predominated in 14 (56%) of the 25 years, seasonal influenza A(H1N1) in 7 (28%), and influenza B i

44 We tested seasonal influenza A(H1N1) viruses collected in 2008-201

45 Two distinct genetic clades of seasonal influenza A(H1N1) viruses have cocirculated in

46 nts compared to immunocompetent controls for seasonal influenza A(H1N1), A(H3N2) and B.

47 aused by individual influenza strains (i.e., seasonal influenza A(H1N1), pandemic A(H1N1), A(H3N2), a

48 ic cross-reactivity among humans primed with seasonal influenza A(H3N2) (sH3N2), using postinfection

49 , in stark contrast to oseltamivir-resistant seasonal influenza A(H3N2) viruses, H7N9 virus replicati

50 0 swine-origin influenza A(H3N2) variant and seasonal influenza A(H3N2).

51 tal of 161 HCT recipients (18 2009 H1N1, 103 seasonal influenza A, and 40 seasonal influenza B) were

52 , and prolonged viral shedding compared with seasonal influenza A.

53 ryngeal specimen sensitivities were 100% for seasonal influenza A/H1 virus and influenza A/H3 virus,

54 2009, oseltamivir resistance developed among seasonal influenza A/H1N1 (sH1N1) virus isolates at an e

55 ate its performance using historical data on seasonal influenza A/H3N2 virus.

56 mismatch on IAV reassortment using the human seasonal influenza A/Panama/2007/99 (H3N2) and pandemic

57 estimate was similar in magnitude to that of seasonal influenza, a marked shift toward mortality amon

58 r a short time afterward with no substantial seasonal influenza activity during that period.

59 Peaks of seasonal influenza activity occur annually in many count

60 , a method to identify the period of highest seasonal influenza activity.

61 rs for Disease Control and Prevention (CDC), seasonal influenza affects 5% to 20% of the U.S. populat

62 The effects of weather variability on seasonal influenza among different age groups remain unc

63 reat due to unpredictable antigenic drift in seasonal influenza and antigenic shifts caused by the em

64 tive as a broadly protective vaccine against seasonal influenza and emerging pandemic threats.IMPORTA

65 ntial for the treatment of both pandemic and seasonal influenza and has a distinct advantage over the

66 o assess human B cell responses to trivalent seasonal influenza and monovalent pandemic H1N1 vaccinat

67 level to quantify the relationships between seasonal influenza and monthly minimum temperature (MIT)

68 ission relative to comparable estimates from seasonal influenza and other directly transmitted infect

69 iral tropism and tissue damage compared with seasonal influenza and prompted further investigation.

70 Seasonal influenza and the 2009 pandemic strain were cha

71 in order to investigate the epidemiology of seasonal influenza and the characteristics of the circul

72 ntification of known risk factors for severe seasonal influenza and the more protracted clinical cour

73 nsive, and widely available, vaccination for seasonal influenza and the novel H1N1 strain is indicate

74 Given the yearly challenge of seasonal influenza and the potential catastrophic conseq

75 associations between weather variability and seasonal influenza, and growth rates of seasonal influen

76 <5 years of age, the mean annual numbers of seasonal influenza- and RSV-associated all-respiratory d

77 In addition, we estimated the seasonal influenza- and RSV-associated deaths among HIV-

78 There are few longitudinal studies of seasonal influenza associated neurological disease (IAND

79 childbearing age, the majority of estimated seasonal influenza-associated deaths occurred in HIV-inf

80 gnant women experienced an increased risk of seasonal influenza-associated mortality compared with no

81 nonpregnant women, the estimated mean annual seasonal influenza-associated mortality rate was 41.2 (8

82 During 1999-2009, the estimated mean annual seasonal influenza-associated mortality rates were 12.6

83 ng pregnant women, the estimated mean annual seasonal influenza-associated mortality rates were 74.9

84 There are few longitudinal studies of seasonal influenza-associated neurological disease (IAND

85 We estimated that 291 243-645 832 seasonal influenza-associated respiratory deaths (4.0-8.

86 ldren who received TIV had a reduced risk of seasonal influenza B confirmed by RT-PCR, with a vaccine

87 2009 H1N1, 103 seasonal influenza A, and 40 seasonal influenza B) were analyzed.

88 accination is a potential solution to reduce seasonal influenza burden.

89 ss analysis, we used a transmission model of seasonal influenza calibrated to 14 seasons of weekly co

90 suggest that previous exposure of humans to seasonal influenza can poise them to respond to avian H7

91 ain outcome is the percentage of prospective seasonal influenza cases identified by the ALERT algorit

92 Seasonal influenza causes >200 000 annual hospitalizatio

93 Seasonal influenza causes substantial morbidity and mort

94 when a group-mismatched HA subtype dominates seasonal influenza circulation.

95 variants, as well as viral escape mutants in seasonal influenza, compromise the buildup of herd immun

96 We applied JRFR to human H3N2 seasonal influenza data from 1968 to 2003.

97 Here we present weekly forecasts of seasonal influenza developed and run in real time for 10

98 Seasonal influenza does not appear to pose a significant

99 In this large cohort, we also show that seasonal influenza does not result in significant alloan

100 Adults hospitalized for seasonal influenza during the period were used for compa

101 in hospitalized children aged <18 years with seasonal influenza (during 2003-2009) and 2009 pandemic

102 Winter holidays delay seasonal influenza epidemic peaks and shift disease risk

103 and seasonal influenza, and growth rates of seasonal influenza epidemics among different age groups

104 of reduced air traffic and the asynchrony of seasonal influenza epidemics among West African countrie

105 Seasonal influenza epidemics and occasional pandemics th

106 vention and treatment for management of both seasonal influenza epidemics and pandemics are desirable

107 Seasonal influenza epidemics cause consistent, considera

108 Seasonal influenza epidemics cause high economic loss, m

109 evelopment of systems capable of forecasting seasonal influenza epidemics in temperate regions in rea

110 Seasonal influenza epidemics offer unique opportunities

111 Seasonal influenza epidemics recur due to antigenic drif

112 During seasonal influenza epidemics, disease burden is shoulder

113 stems that are able to predict irregular non-seasonal influenza epidemics, using either the ensemble

114 ans in defining the community-level onset of seasonal influenza epidemics.

115 igher rates of illness and death than annual seasonal influenza epidemics.

116 's magnitude was similar to that seen during seasonal influenza epidemics.

117 eronegative and experimentally infected with seasonal influenza H1N1 A/Brisbane/59/07 virus.

118 Mice that were inoculated with a seasonal influenza H1N1 virus followed by infection with

119 s strain (A/California/4/09 [CA09]), a human seasonal influenza H1N1 virus isolate (A/New Caledonia/2

120 Asn 177, but not Asn 71 and Asn 104) from a seasonal influenza H1N1 virus, A/Solomon Islands/2006 (S

121 prepared from an antigenically related 1992 seasonal influenza H3N2 (A/Beijing/32/1992) virus failed

122 Seasonal influenza has been associated with greater morb

123 ledge, this is the first time predictions of seasonal influenza have been made in real time and with

124 These results support the safety of seasonal influenza immunization during pregnancy and sug

125 xtending the established benefits of current seasonal influenza immunizations.

126 ng oseltamivir with placebo for treatment of seasonal influenza in adults regarding symptom alleviati

127 009 H1N1) leads to more serious disease than seasonal influenza in hematopoietic cell transplant (HCT

128 We aimed to quantify mortality due to seasonal influenza in Thailand, a tropical middle-income

129 arison with a similarly standardized HFR for seasonal influenza in the same setting.

130 when there was essentially no circulation of seasonal influenza in the United States, and 2007/2008,

131 (H1N1)pdm09 were more likely than women with seasonal influenza infection to be hospitalized within 3

132 of cross-reactive CD4 T cells generated from seasonal influenza infection were found to expand earlie

133 on, diagnosis, management, and prevention of seasonal influenza infection.

134 ly with ADCC-Abs to H7N9 NP, suggesting that seasonal influenza infections and vaccinations may induc

135 Seasonal influenza infections are associated with substa

136 such as the differences between pandemic and seasonal influenza infections.

137 Seasonal influenza infects approximately 5-20% of the U.

138 Seasonal influenza is a major cause of mortality worldwi

139 Seasonal influenza is a vaccine-preventable disease that

140 Seasonal influenza is an important cause of acute neurol

141 Seasonal influenza is controlled through vaccination cam

142 Seasonal influenza is efficiently transmitted from human

143 showed that the antigenic evolution of H3N2 seasonal influenza is generally S-shaped while the genet

144 unger (median age, 47 years) than those with seasonal influenza (median age, 68 years; P < .01), and

145 opical and temperate zones, but estimates of seasonal influenza mortality in developing countries in

146 diagnosis codes in adults hospitalized with seasonal influenza (n = 5270) or 2009 pandemic influenza

147 Similarly, vaccines against seasonal influenza need to be updated frequently to prot

148 Seasonal influenza outbreaks and recurrent influenza pan

149 perience of gradual or regional closures for seasonal influenza outbreaks demonstrates that logistic

150 ing, peak incidence, and total incidence for seasonal influenza outbreaks in 48 states and 95 cities

151 e thousands of deaths that occur from annual seasonal influenza outbreaks, despite the possibility of

152 work for initializing real-time forecasts of seasonal influenza outbreaks, using a data assimilation

153 produced a number of methods for forecasting seasonal influenza outbreaks.

154 Compared to seasonal influenza, patients with pandemic 2009 influenz

155 bial prescribing for FRI during pandemic and seasonal influenza periods.

156 such as a pandemic strain versus a previous seasonal influenza, plays a crucial role in the monitori

157 nts reported assessing need for and stocking seasonal influenza; pneumococcal; tetanus and diphtheria

158 Recently, we developed a seasonal influenza prediction system that uses an advanc

159 For a seasonal influenza product, manufacturing, distribution,

160 In the models with seasonal influenza rates included, observed IPP rates du

161 lts aged 65 years and older account for most seasonal influenza-related hospital admissions and death

162 Vaccine effectiveness was variable for seasonal influenza: six (35%) of 17 analyses in nine stu

163 4, H1N1pdm09 became North America's dominant seasonal influenza strain.

164 ults indicate prior infection with different seasonal influenza strains leads to radically different

165 By comparing human seasonal influenza strains to avian influenza viruses, w

166 LAIV) are safe for use in protection against seasonal influenza strains, concerns regarding their pot

167 al-time risk assessments hinging on reliable seasonal influenza surveillance and precise estimates of

168 ate data involving 269 ferrets infected with seasonal influenza, swine influenza, and highly pathogen

169 Conversely, for seasonal influenza the detection rate was highest in chi

170 zation could slow the antigenic evolution of seasonal influenza; these effects have profound implicat

171 lutinin (HA)-specific CD4 T-cell memory with seasonal influenza to facilitate antibody production to

172 n this study, we quantified the potential of seasonal influenza to provide memory CD4 T cells that ca

173 ariability appears to be more influential on seasonal influenza transmission in younger (0-14) age gr

174 e to our knowledge in children, tonsils from seasonal influenza-vaccinated children.

175 The efficacy of seasonal influenza vaccination against 2009 pandemic inf

176 Recent receipt of seasonal influenza vaccination and older age were associ

177 Similarly, the serological responses to seasonal influenza vaccination are also determined large

178 In a randomized, controlled trial of seasonal influenza vaccination in 773 children aged 6-17

179 The role of seasonal influenza vaccination in pandemic influenza A H

180 Safety and immunogenicity data of seasonal influenza vaccination in transplanted patients

181 t this hypothesis, we examined the effect of seasonal influenza vaccination on NK cell function and p

182 3N2)v] highlights the need to assess whether seasonal influenza vaccination provides cross-protection

183 ic H1N1 vaccination, as well as pre-pandemic seasonal influenza vaccination to elucidate the effect o

184 ages frequently underperform in response to seasonal influenza vaccination, despite virologic contro

185 After 21 d, subjects received the seasonal influenza vaccination.

186 ansplant recipients before and 1 month after seasonal influenza vaccination.

187 B-cell responses get boosted in humans after seasonal influenza vaccination.

188 ith previous estimates of the disorder after seasonal influenza vaccination.

189 munization and memory B cells isolated after seasonal influenza vaccination.

190 tested this by examining the ability of live seasonal influenza vaccine (FluMist) to mediate protecti

191 antibody response to a trivalent inactivated seasonal influenza vaccine (TIV) and a large number of i

192 Prior receipt of a trivalent seasonal influenza vaccine (TIV) can affect hemagglutina

193 l investigation of 274 children who received seasonal influenza vaccine (trivalent inactivated vaccin

194 y, and diabetic subjects vaccinated with the seasonal influenza vaccine across five consecutive seaso

195 determine the effectiveness of the 2010-2011 seasonal influenza vaccine against laboratory-confirmed

196 hildren previously vaccinated with 2009-2010 seasonal influenza vaccine also showed greater expansion

197 eiving one dose of the nonadjuvant 2010-2011 seasonal influenza vaccine and determined the immunologi

198 e effectiveness (VE) estimates for 2015-2016 seasonal influenza vaccine are reported from Canada's Se

199 nd adaptive response to vaccination with the seasonal influenza vaccine during early childhood, and i

200 Seasonal influenza vaccine formulas change almost every

201 Seasonal influenza vaccine formulation efforts struggle

202 s were stratified by documented receipt of a seasonal influenza vaccine in each Medicare beneficiary.

203 Antibody responses to the inactivated seasonal influenza vaccine in patients with atopic derma

204 bserved during 2009/2010, when any effect of seasonal influenza vaccine observed during all time peri

205 would be difficult to capture during routine seasonal influenza vaccine programmes, which have extens

206 campaign and was comparable to some previous seasonal influenza vaccine risk assessments.

207 of the antibodies induced by the inactivated seasonal influenza vaccine toward the 2009 pandemic H1N1

208 The unadjuvanted 2012-2013 seasonal influenza vaccine was administered to 81 kidney

209 Receipt of the 2010-2011 seasonal influenza vaccine was associated with a 42% (95

210 The 2016-2017 seasonal influenza vaccine was updated to include a clad

211 Influenza C is not included in the annual seasonal influenza vaccine, and has historically been re

212 ple, we analyse CD4+ T-cell responses to the seasonal influenza vaccine, establishing a frequency hie

213 and the limited cross-protective effect from seasonal influenza vaccine, the majority of children are

214 es, are selected for inclusion in the annual seasonal influenza vaccine.

215 tional, and immunologic data in humans given seasonal influenza vaccine.

216 of young and elderly adults with inactivated seasonal influenza vaccine.

217 1 strain is being incorporated into the 2010 seasonal influenza vaccine.

218 infected children who received the 2012-2013 seasonal influenza vaccine.

219 before and after vaccination with trivalent seasonal influenza vaccine.

220 ited range of protection provided by current seasonal influenza vaccines and towards a future with a

221 Antibody responses to seasonal influenza vaccines are defective during older a

222 riable epitopes in the HA head; (ii) current seasonal influenza vaccines are efficient in inducing B-

223 Seasonal influenza vaccines are transitioning to quadriv

224 Our data indicate that vaccination with the seasonal influenza vaccines did not confer complete prot

225 from adults ages 48-64 who received multiple seasonal influenza vaccines from 2004 to 2009 for cross-

226 Two different types of seasonal influenza vaccines have been used on the market

227 d for both nonadjuvanted and MF59-adjuvanted seasonal influenza vaccines in elderly recipients.

228 Effectiveness of seasonal influenza vaccines mainly depends upon how well

229 The impact of contemporary seasonal influenza vaccines on establishing immunity to

230 d States, including subjects vaccinated with seasonal influenza vaccines or with confirmed seasonal v

231 of the consistency of protection induced by seasonal influenza vaccines over the duration of a full

232 lar to that observed after administration of seasonal influenza vaccines over the past several years.

233 Although annual seasonal influenza vaccines provide some protection agai

234 vent profiles induced by these two groups of seasonal influenza vaccines were studied based on the da

235 lts provide evidence that supplementation of seasonal influenza vaccines with M2 VLPs is a promising

236 he inclusion of both influenza B lineages in seasonal influenza vaccines.

237 s from studies with the yellow fever and the seasonal influenza vaccines.

238 slightly higher than that seen with previous seasonal influenza vaccines; however, additional results

239 nogenic influenza A epitopes as putative non-seasonal influenza vaccines; one specifically targets th

240 against cell culture-confirmed infection by seasonal influenza virus and significantly reduces the d

241 We applied this model into H3N2 seasonal influenza virus data.

242 Seasonal influenza virus epidemics represent a significa

243 tential of D1-8 for therapeutic treatment of seasonal influenza virus H3 infection.

244 The antigenic distance between current seasonal influenza virus H3 strains in humans and those

245 nza A virus is less stable than other recent seasonal influenza virus HAs, but the molecular interact

246 The global burden of disease attributable to seasonal influenza virus in children is unknown.

247 nogenicity to provide better protection from seasonal influenza virus infection and improve pandemic

248 Mothers with seasonal influenza virus infection had an increased risk

249 Seasonal influenza virus infection presents a major stra

250 Seasonal influenza virus infection was found to be assoc

251 vaccine platform used for the prevention of seasonal influenza virus infection.

252 Seasonal influenza virus infections continue to cause si

253 ens contributing to a significant portion of seasonal influenza virus infections worldwide.

254 In contrast to seasonal influenza virus infections, which typically cau

255 ual vaccinations, there are few remedies for seasonal influenza virus infections.

256 or without CLDC, and challenged with a human seasonal influenza virus isolate, A/Memphis/7/2001(H1N1)

257 gnosis of influenza during a period in which seasonal influenza virus or A(H1N1)pdm09 was the predomi

258 In summary, prior infection with a seasonal influenza virus or s-LAIV primed mice for a rob

259 tions about the makeup of the future A(H3N2) seasonal influenza virus population, and we compare pred

260 ragine or threonine in over 99% of all human seasonal influenza virus pre-2009 H1N1, H2N2, and H3N2 s

261 ich prior infection with specific strains of seasonal influenza virus protect from lethal H5N1 challe

262 Thus, in primate cells, MxA inhibits human seasonal influenza virus replication at a step prior to

263 Seasonal influenza virus routinely causes epidemic infec

264 satory effect of E214D is applicable in both seasonal influenza virus strain A/New Caledonia/20/1999

265 sed to determine when sequence variations in seasonal influenza virus strains have affected regions r

266 cross-reactivity between strains in pigs and seasonal influenza virus strains in humans is also impor

267 d issue is how infection or vaccination with seasonal influenza virus strains influences the ability

268 h or without prior exposure to either of two seasonal influenza virus strains, H1N1 and H3N2.

269 dm09] is less stable than the HAs from other seasonal influenza virus strains.

270 o observations from outside of Africa and to seasonal influenza virus strains.

271 mans following infection or vaccination with seasonal influenza virus strains.

272 thesized that it is possible to make a human seasonal influenza virus that is specifically attenuated

273 orating NA, including PIV5-NA, could improve seasonal influenza virus vaccine efficacy and provide pr

274 ns of emergence and circulation of new human seasonal influenza virus variants is a key scientific an

275 us with that of mice infected by a nonlethal seasonal influenza virus, A/Texas/36/91.

276 .1%) and 131 (5.7%) yielded A(H1N1)pdm09 and seasonal influenza virus, respectively.

277 es of H1N1 pandemic, H1N1 seasonal, and H3N2 seasonal influenza virus.

278 Seasonal influenza viruses are a common cause of acute r

279 Continual and rapid mutation of seasonal influenza viruses by antigenic drift necessitat

280 nza and emerging pandemic threats.IMPORTANCE Seasonal influenza viruses cause considerable morbidity

281 Seasonal influenza viruses continuously drift, which all

282 Seasonal influenza viruses evolve rapidly, allowing them

283 Human seasonal influenza viruses evolve rapidly, enabling the

284 s of 9,604 haemagglutinin sequences of human seasonal influenza viruses from 2000 to 2012.

285 in the proteolytic activation and spread of seasonal influenza viruses in humans.IMPORTANCE Influenz

286 Antigenic drift of circulating seasonal influenza viruses necessitates an international

287 In comparison to seasonal influenza viruses of lesser virulence, the 1918

288 Increased antibody diversity to seasonal influenza viruses was associated with low-level

289 owever, the specific proteases that activate seasonal influenza viruses, especially H3N2 viruses, in

290 way epithelial cells was on par with that of seasonal influenza viruses, mild-to-moderate disease was

291 For seasonal influenza viruses, protection is correlated wit

292 A(H3N2)v viruses transmit as efficiently as seasonal influenza viruses, raising concern over the pan

293 Compared to seasonal influenza viruses, the 2009 pandemic H1N1 (pH1N

294 role of H5N1 PA in altering the virulence of seasonal influenza viruses, we generated a recombinant s

295 nces in the immune responses to pandemic and seasonal influenza viruses.

296 its introduction into currently circulating seasonal influenza viruses.

297 ng by previous vaccination or infection with seasonal influenza viruses.

298 In a year with minimal seasonal influenza, we found no evidence that confoundin

299 Those with seasonal influenza were younger (median 4.4 vs 8.7 years

300 volution allows the continual circulation of seasonal influenza, while novel influenza viruses invade